ArticleAnnals of medicine2026
Correlation of foot process effacement with clinicopathological features and short-term prognosis in IgA nephropathy.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare clinicopathological characteristics and short-term renal outcomes of IgA nephropathy (IgAN) patients with varying degrees of foot process effacement (FPE).
methodsThis multicenter retrospective study evaluated 1,001 biopsy-proven IgAN patients grouped by FPE severity (mild, moderate, severe). Regression models identified factors associated with different FPE degrees. Short-term outcomes in a 1-year follow-up subset were analyzed using overlap weighting, Cox regression, and Kaplan-Meier analysis.
resultsThe cohort comprised 38.8% mild, 49.6% moderate, and 11.6% severe FPE cases. Greater FPE severity corresponded with elevated blood pressure, proteinuria, and anemia, alongside decreased estimated glomerular filtration rate (eGFR) and albumin levels. Pathologically, worsening FPE correlated with advanced mesangial hyperplasia and tubulointerstitial damage. Severe FPE was distinctively associated with higher serum phosphorus, endocapillary hypercellularity (E1), and progressive interstitial fibrosis (T). Among 486 followed patients, complete remission rates were significantly lower in the severe FPE group than in the mild group (HR = 0.475,
conclusionsThe degree of FPE in IgAN was significantly positively correlated with proteinuria, hypoalbuminemia, eGFR decline, mesangial hypercellularity, and tubular atrophy/interstitial fibrosis. Severe FPE is an independent risk factor influencing short-term renal outcomes in IgAN patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.